

Angela Nebbioso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/178979/publications.pdf>

Version: 2024-02-01

116
papers

6,475
citations

71004

43
h-index

81351

76
g-index

118
all docs

118
docs citations

118
times ranked

11289
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of AIF/CypA Lethal Pathway in SH-SY5Y Cells Treated with Staurosporine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 265.	1.8	5
2	SIRT1 pharmacological activation rescues vascular dysfunction and prevents thrombosis in MTHFR deficiency. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	14
3	Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis. <i>Epigenetics</i> , 2021, 16, 838-850.	1.3	21
4	Different Approaches to Unveil Biomolecule Configurations and Their Mutual Interactions. <i>Analytical Letters</i> , 2021, 54, 40-56.	1.0	1
5	Novel Pyridine-Based Hydroxamates and 2-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. <i>ChemMedChem</i> , 2021, 16, 989-999.	1.6	8
6	The Role of Necroptosis: Biological Relevance and Its Involvement in Cancer. <i>Cancers</i> , 2021, 13, 684.	1.7	27
7	Gene Transactivation and Transrepression in MYC-Driven Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3458.	1.8	18
8	Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1. <i>Viruses</i> , 2021, 13, 1263.	1.5	53
9	Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy. <i>Marine Drugs</i> , 2021, 19, 15.	2.2	12
10	KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 750315.	1.3	17
11	DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. <i>Epigenetics</i> , 2020, 15, 439-453.	1.3	46
12	SIRT1 Activation by Natural Phytochemicals: An Overview. <i>Frontiers in Pharmacology</i> , 2020, 11, 1225.	1.6	146
13	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 799.	1.3	15
14	The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line. <i>Frontiers in Oncology</i> , 2020, 10, 820.	1.3	8
15	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. <i>Cancers</i> , 2020, 12, 447.	1.7	8
16	Trifolium Repens Blocks Proliferation in Chronic Myelogenous Leukemia via the BCR-ABL/STAT5 Pathway. <i>Cells</i> , 2020, 9, 379.	1.8	12
17	Comparative Phytochemical Characterization, Genetic Profile, and Antiproliferative Activity of Polyphenol-Rich Extracts from Pigmented Tubers of Different Solanum tuberosum Varieties. <i>Molecules</i> , 2020, 25, 233.	1.7	29
18	Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence. <i>Epigenetics</i> , 2020, 15, 664-683.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2020, 21, e51028.	2.0	1
20	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. <i>Clinical Epigenetics</i> , 2019, 11, 68.	1.8	30
21	BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. <i>Cell Death and Disease</i> , 2019, 10, 338.	2.7	31
22	Discovery of the First-in-Class GSK-3 β /HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 469-474.	1.3	32
23	Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype. <i>Frontiers in Pharmacology</i> , 2019, 10, 38.	1.6	128
24	Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5654.	1.8	16
25	Inhibition of Histone Demethylases LSD1 and UTX Regulates ER α Signaling in Breast Cancer. <i>Cancers</i> , 2019, 11, 2027.	1.7	34
26	Oxidative nucleophilic substitution selectively produces cambinol derivatives with antiproliferative activity on bladder cancer cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 78-82.	1.0	12
27	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 290-320.	2.6	31
28	The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia. <i>Oncogene</i> , 2018, 37, 2559-2572.	2.6	32
29	Designing Dual Transglutaminase-2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. <i>ChemMedChem</i> , 2018, 13, 227-230.	1.6	13
30	RIP1-HAT1-SIRT Complex Identification and Targeting in Treatment and Prevention of Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2886-2900.	3.2	40
31	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. <i>Oncotarget</i> , 2018, 9, 25647-25660.	0.8	13
32	Biological interactions of biocompatible and water-dispersed MoS ₂ nanosheets with bacteria and human cells. <i>Scientific Reports</i> , 2018, 8, 16386.	1.6	66
33	3-Chloro-N-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1006.	1.6	14
34	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 127-138.	2.6	39
35	Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me _{2/3} Demethylases GSKJ4 Inhibitor via Protein Kinase A. <i>Frontiers in Pharmacology</i> , 2018, 9, 792.	1.6	13
36	Synthesis and Biological Evaluation of Tripartin, a Putative KDM4 Natural Product Inhibitor, and 1-(Dichloromethyl)indenol Analogues. <i>ChemMedChem</i> , 2018, 13, 1949-1956.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Cancer epigenetics: Moving forward. <i>PLoS Genetics</i> , 2018, 14, e1007362.	1.5	364
38	Combined HAT/EZH2 modulation leads to cancer-selective cell death. <i>Oncotarget</i> , 2018, 9, 25630-25646.	0.8	5
39	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2542-2555.	3.2	105
40	Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2344-2360.	2.9	82
41	Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses. <i>Scientific Reports</i> , 2017, 7, 11725.	1.6	11
42	Identification and characterization of PKF118-310 as a KDM4A inhibitor. <i>Epigenetics</i> , 2017, 12, 198-205.	1.3	36
43	1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1471-1491.	2.9	60
44	Stockpile of Slight Transcriptomic Changes Determines the Indirect Genotoxicity of Low-Dose BPA in Thyroid Cells. <i>PLoS ONE</i> , 2016, 11, e0151618.	1.1	32
45	HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. <i>Oncotarget</i> , 2015, 6, 886-901.	0.8	27
46	Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1187-1202.	1.5	16
47	Anticancer activities of anthocyanin extract from genotyped <i>Solanum tuberosum</i> L. Vitelotte. <i>Journal of Functional Foods</i> , 2015, 19, 584-593.	1.6	43
48	ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. <i>Epigenetics</i> , 2015, 10, 6-18.	1.3	29
49	Antiproliferative, Antibacterial and Antifungal Activity of the Lichen <i>Xanthoria parietina</i> and Its Secondary Metabolite Parietin. <i>International Journal of Molecular Sciences</i> , 2015, 16, 7861-7875.	1.8	77
50	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. <i>Cancer Research</i> , 2014, 74, 2328-2339.	0.4	33
51	Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLf and pERK present in human erythroid cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 50, 112-122.	1.2	23
52	Evaluation of a large library of (thiazol-2-yl)hydrazones and analogues as histone acetyltransferase inhibitors: Enzyme and cellular studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 80, 569-578.	2.6	54
53	1,3,4-Oxadiazole-Containing Histone Deacetylase Inhibitors: Anticancer Activities in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6259-6265.	2.9	102
54	Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 973-978.	1.3	13

#	ARTICLE	IF	CITATIONS
55	Natural compounds in epigenetics: A current view. <i>Food and Chemical Toxicology</i> , 2014, 73, 71-83.	1.8	35
56	Analysis of Chromatin-Nuclear Receptor Interactions by Laser-Chromatin Immunoprecipitation. <i>Methods in Molecular Biology</i> , 2014, 1204, 25-34.	0.4	2
57	Histone deacetylase inhibitors: a patent review (2009 - 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 1-17.	2.4	37
58	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 56-68.	2.6	16
59	<i>Genista sessilifolia</i> DC . extracts induce apoptosis across a range of cancer cell lines. <i>Cell Proliferation</i> , 2013, 46, 183-192.	2.4	22
60	HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. <i>PLoS ONE</i> , 2013, 8, e83018.	1.1	40
61	Trials with -epigenetic-™ drugs: An update. <i>Molecular Oncology</i> , 2012, 6, 657-682.	2.1	208
62	UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. <i>Oncogene</i> , 2012, 31, 5061-5072.	2.6	77
63	Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead. <i>MedChemComm</i> , 2012, 3, 298-304.	3.5	7
64	Indole-Derived Psammaphin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9467-9491.	2.9	48
65	Rarity of Human T Helper 17 Cells Is due to Retinoic Acid Orphan Receptor-Dependent Mechanisms that Limit Their Expansion. <i>Immunity</i> , 2012, 36, 201-214.	6.6	103
66	The new low-toxic histone deacetylase inhibitor <i>S</i>-2 induces apoptosis in various acute myeloid leukaemia cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1758-1765.	1.6	14
67	Discovery of Salermide-Related Sirtuin Inhibitors: Binding Mode Studies and Antiproliferative Effects in Cancer Cells Including Cancer Stem Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10937-10947.	2.9	84
68	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. <i>Leukemia</i> , 2012, 26, 662-674.	3.3	72
69	Sirtuins and Disease: The Road Ahead. <i>Frontiers in Pharmacology</i> , 2012, 3, 4.	1.6	157
70	Nonlinear protein - nucleic acid crosslinking induced by femtosecond UV laser pulses in living cells. <i>Laser Physics Letters</i> , 2012, 9, 234-239.	0.6	21
71	Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1256-1266.	1.6	16
72	<i>Psidium guajava</i> L. anti-neoplastic effects: induction of apoptosis and cell differentiation. <i>Cell Proliferation</i> , 2012, 45, 22-31.	2.4	45

#	ARTICLE	IF	CITATIONS
73	Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 131-145.	0.8	28
74	Novel Cinnamyl Hydroxyamides and 2- α -Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. <i>ChemMedChem</i> , 2011, 6, 698-712.	1.6	17
75	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3637-3649.	1.4	52
76	Simplification of the tetracyclic SIRT1-selective inhibitor MC2141: Coumarin- and pyrimidine-based SIRT1/2 inhibitors with different selectivity profile. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 3659-3668.	1.4	30
77	Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2394-2404.	1.9	49
78	N ^ε -lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2795-2800.	3.3	93
79	Histone deacetylase inhibitors: clinical implications for hematological malignancies. <i>Clinical Epigenetics</i> , 2010, 1, 25-44.	1.8	20
80	PML-RAR α /RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. <i>Cancer Cell</i> , 2010, 17, 173-185.	7.7	276
81	Identification of Tri- and Tetracyclic Pyrimidinediones as Sirtuin Inhibitors. <i>ChemMedChem</i> , 2010, 5, 674-677.	1.6	40
82	Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. <i>Oncogene</i> , 2010, 29, 105-116.	2.6	73
83	Epigenetic Silencing of Peroxisome Proliferator-Activated Receptor δ Is a Biomarker for Colorectal Cancer Progression and Adverse Patients' Outcome. <i>PLoS ONE</i> , 2010, 5, e14229.	1.1	69
84	HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 219-228.	1.1	53
85	Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPAR δ /RXR Heterodimers to Activate the Intrinsic Death Pathway by NO. <i>Cancer Cell</i> , 2009, 16, 220-231.	7.7	31
86	Pyrrrole-Based Hydroxamates and 2- α -Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities. <i>ChemMedChem</i> , 2009, 4, 1411-1415.	1.6	9
87	Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. <i>EMBO Reports</i> , 2009, 10, 776-782.	2.0	125
88	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. <i>Oncogene</i> , 2009, 28, 781-791.	2.6	244
89	Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1132-1135.	1.0	63
90	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6284-6288.	1.0	12

#	ARTICLE	IF	CITATIONS
91	TNF-related apoptosis-inducing ligand: Signalling of a "smart" molecule. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 460-466.	1.2	23
92	New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 235-247.	1.2	24
93	Study of 1,4-Dihydropyridine Structural Scaffold: Discovery of Novel Sirtuin Activators and Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5496-5504.	2.9	147
94	Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells. <i>Journal of Translational Medicine</i> , 2009, 7, 48.	1.8	27
95	Synthesis of Benzamides Related to Anacardic Acid and Their Histone Acetyltransferase (HAT) Inhibitory Activities. <i>ChemMedChem</i> , 2008, 3, 1435-1442.	1.6	52
96	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7992-8002.	1.4	11
97	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: Histone deacetylase inhibition and in-cell activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2530-2535.	1.0	22
98	Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2788-2792.	1.0	96
99	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2030-2038.	1.9	48
100	Effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. <i>Journal of Translational Medicine</i> , 2008, 6, 27.	1.8	18
101	Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2279-2290.	2.9	133
102	Histone deacetylase inhibitors and hemoglobin F induction in β^2 -thalassemia. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2341-2347.	1.2	14
103	Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia. <i>Molecular Pharmacology</i> , 2007, 72, 1111-1123.	1.0	30
104	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1510-1522.	1.2	13
105	Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1902-1914.	1.2	89
106	Bispyridinium Dienes: Histone Deacetylase Inhibitors with Selective Activities. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2497-2505.	2.9	48
107	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. <i>ChemMedChem</i> , 2007, 2, 987-991.	1.6	52
108	Small-Molecule Inhibitors of Histone Acetyltransferase Activity: Identification and Biological Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6897-6907.	2.9	134

#	ARTICLE	IF	CITATIONS
109	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6046-6056.	2.9	57
110	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1163-1184.	1.2	43
111	Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2006, 12, 6133-6143.	3.2	39
112	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. <i>Nature Medicine</i> , 2005, 11, 77-84.	15.2	567
113	Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A-Mediated Desubordination of Retinoid X Receptor. <i>Cancer Research</i> , 2005, 65, 8754-8765.	0.4	111
114	TRAIL: At the Center of Drugable Anti-Tumor Pathways. <i>Cell Cycle</i> , 2005, 4, 914-918.	1.3	13
115	Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1752-1762.	1.2	47
116	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3344-3353.	2.9	193